Article Text

AB0373 Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
  1. B. Combe1,
  2. D. Veale2,
  3. R. Burgos-Vargas3,
  4. G. Szűcs4,
  5. M. Leirisalo-Repo5,
  6. R. Yao6,
  7. S. Huyck6,
  8. R. Lyu6,
  9. M. Govoni7,
  10. N. Vastesaeger8,
  11. H.H. Weng6
  1. 1Hôpital Lapeyronie, Montpellier, France
  2. 2St. Vincent's University Hospital, Dublin, Ireland
  3. 3Cliditer S.A. de C.V. and Hospital General de Mexico, Mexico City, Mexico
  4. 4University of Debrecen Medical and Health Science Center, Debrecen, Hungary
  5. 5Helsinki University Central Hospital, Helsinki, Finland
  6. 6Merck, Kenilworth, United States
  7. 7MSD Italy, Rome, Italy
  8. 8MSD Belgium, Brussels, Belgium


Background Physicians, patients, and payers may have different ideas about what constitutes successful treatment and how treatment goals should be defined for rheumatoid arthritis (RA).

Objectives To evaluate the overlap between attained treatment goals that are important to physicians, patients, and payers after 6 months of add-on golimumab (GLM) treatment in patients with active RA, and to determine baseline predictors of patients who achieve all 3 treatment goals represented by these stakeholders.

Methods GO-MORE was an open-label, multinational, prospective study in biologic-naïve patients with active RA (28-joint disease activity score using erythrocyte sedimentation rate [DAS28-ESR] ≥3.2) despite disease-modifying antirheumatic drug (DMARD) treatment. Patients received 50-mg subcutaneous (SC) GLM once monthly for 6 months. Efficacy outcomes including DAS28-ESR, patient-acceptable symptom state (PASS), and EuroQol 5-dimension (EQ-5D) were evaluated at month 6. PASS was assessed with 1 yes/no question as to whether the patient would be satisfied to stay in their current disease state. The extent of overlap in achievement of strict remission treatment goals was evaluated (DAS28-ESR remission, normal EQ-5D [≥.8], and met PASS); looser low disease activity (LDA) treatment goals were also evaluated (DAS28-ESR LDA, EQ-5D near normal [≥.7], and met PASS). A multivariate regression analysis identified baseline predictors of patients who achieved the intersection of the 3 criteria.

Results In 3280 efficacy-evaluable patients, mean disease duration was 7.6 years; mean DAS28–ESR was 5.97 (SD=1.095). As previously reported, 23.9% of 3280 efficacy-evaluable patients achieved remission, and 37.4% achieved LDA (based on DAS28-ESR) at month 6.1 21% of patients achieved normal QoL, and 48% achieved close-to-normal QoL (EQ-5D ≥.7). 66.0% of patients achieved PASS. Overlap in patients who achieved each treatment goal is shown in the figure. 10.7% of patients (350/3280) met all 3 strict criteria, and 25.1% (823/3280) met all 3 looser criteria. Significant baseline predictors of achieving all 3 strict remission criteria were absence of comorbidities; lower DAS28, Health Assessment Questionnaire (HAQ), and swollen joint count scores; and greater anti-cyclic citrullinated peptide levels and EQ-5D Index scores. When PASS was replaced with HAQ ≤.5 (minimal or no functional impairment, achieved by 37.4% of patients) in either the set of strict or looser criteria, the percentage of patients who met all 3 criteria was similar to when PASS was used.

Figure 1.

Overlap in achieving strict and looser treatment goals.

Conclusions In patients with active RA who failed ≥1 DMARD and received add-on GLM for 6 months, overlap in achievement of LDA goals of physicians, patients, and payers was attained in 25.1% of patients. Overlap was smaller when strict remission goals were evaluated. Several measures of lower disease activity at baseline predicted achievement of all 3 strict remission criteria.


  1. Combe B et al. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-203229.

Disclosure of Interest B. Combe Grant/research support: Pfizer and Roche-Chugai, Consultant for: Merck, Pfizer, Roche-Chugai, and UCB, D. Veale Grant/research support: Abbott, MSD, Pfizer, and Roche, Consultant for: MSD, Pfizer, Roche, and UCB, Speakers bureau: MSD, Pfizer, Roche, and UCB, R. Burgos-Vargas Speakers bureau: BMS, Janssen, Roche, Pfizer, and UCB, G. Szűcs: None declared, M. Leirisalo-Repo Consultant for: MSD, R. Yao Employee of: Merck, S. Huyck Employee of: Merck, R. Lyu Employee of: Merck, M. Govoni Employee of: Merck, N. Vastesaeger Employee of: Merck, H. Weng Employee of: Merck

DOI 10.1136/annrheumdis-2014-eular.1185

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.